Last edition
News about "Ascentage, Innovent Biologics ink pact to commerci"
Ascentage Pharma and Innovent Biologics announced a multifaceted strategic collaboration. This collaboration includes the joint clinical development and commercialization of HQP1351(olverembatinib), a third-generation BCR-ABL inhibitor and a core drug candidate of Ascentage Pharma
Ascentage, Innovent Biologics Ink Pact To Commerci | 16/07/2021 | By Darshana | 461
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members